Entrada Therapeutics publishes corporate presentation on genetic medicines pipeline for neuromuscular and inherited retinal diseases - TRDA News | RalliesEntrada Therapeutics publishes corporate presentation on genetic medicines pipeline for neuromuscular and inherited retinal diseases
T
TRDA• Corporate presentation outlines 2026 clinical data catalysts
- Entrada Therapeutics outlined four clinical data catalysts in 2026 across Duchenne muscular dystrophy and partnered myotonic dystrophy type 1.
- ENTR-601-44 Phase 1/2 Cohort 1 at 6 mg/kg showed no serious adverse events or discontinuations; renal markers stayed within normal range.
- Cohort 1 showed statistically significant improvement versus placebo in Time to Rise of 2.4 seconds, Time to Rise Velocity of 0.09 rises/second.
- ENTR-601-44 Cohort 1 open-label function and safety data are expected by year-end 2026; Cohort 2 at 12 mg/kg data are expected in Q1 2027.
- ENTR-601-45 Cohort 1 data are expected in October 2026; Vertex plans to share VX-670 Phase 1/2 multiple-ascending-dose results in H2 2026.
GNSS
•
